Xcelience® Celebrates 25% Growth in 2013
News Sep 23, 2013
Xcelience has announced the completion of a milestone 25 percent increase in staff since September of 2012, growing from 85 team members then to 113.
“We’re going through a period of robust growth,” says Derek Hennecke, CEO and President. “We’ve added team members to Formulation, Preformulation and Analytical, as well as growing our new Clinical Supply Services (CSS) division. We’re also exploring new growth in commercial development with three projects on track to produce registration batches next year.”
“Most of our new employees were recruited from a strong pool of candidates here in Tampa, but we also bring talent from New Jersey, Connecticut and other states,” Hennecke says.
Hennecke continued, “The 28 new team members we’ve added in the last year have brought fresh ideas and new efficiencies to the business. As CEO I’ve learned that the best thing I can do is hire top talent and then get out of their way.”
Many of the new employees work in the company’s CSS facility located on Grace Street in Tampa, which celebrated the grand opening with a ribbon-cutting ceremony in September 2012.
“CSS has now produced well over one hundred batches and introduced a new blister and bottling line in January of this year,” says Hennecke.
“I can’t tell you how exciting it has been to show clients and potential clients our CSS capabilities and services,” says Clinical Packaging Manager, Damian Gant. “We are the only CDMO specifically targeting the clinical supplies market with a small-scale flexible service. Other companies have tried to scale down large production facilities to produce for this market, but scaling down is a bit like driving an RV to work. A large company can do the job, but it’s expensive, inflexible, inefficient, and frankly, not cut out for the job.”
“Xcelience is the only American CDMO under $2 billion in revenue that has created an entire division devoted specifically to clinical trial clients with their small runs and highly flexible production and distribution needs,” Gant adds. “The growth potential within this market is tremendous.”
Xcelience’s Formulation and Manufacturing divisions also celebrated a landmark this year, with the production of Xcelience’s four millionth Xcelodose capsule. This accomplishment cements the company’s position as an industry leader in the expertise of precision API micro-dosing.
Xcelience was the first CDMO to introduce the Xcelodose into the United States in 2005 and now operates five machines, most of which can produce upwards of 66,000 capsules per month.
Comments | 0 ADD COMMENT
Orphan Drugs and Rare Diseases Global Congress 2017 USA
Sep 12 - Sep 14, 2017